Dopamine and risky decision-making in gambling disorder

https://doi.org/10.1523/ENeURO.0461-19.2020

Cite as: eNeuro 2020; 10.1523/ENeURO.0461-19.2020

Received: 5 November 2019
Revised: 15 April 2020
Accepted: 17 April 2020

This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.

Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Copyright © 2020 Peters et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Dopamine and risky decision-making in gambling disorder.

Jan Peters¹, Taylor Vega², Dawn Weinstein³, Jennifer Mitchell³,⁴ & Andrew Kayser²,⁴

¹Department of Psychology, Biological Psychology, University of Cologne, German
²Department of Neurology, VA Northern California Healthcare System, United States
³Department of Psychiatry, University of California, San Francisco, United States
⁴Department of Neurology, University of California, San Francisco, United States

Corresponding author: jan.peters@uni-koeln.de

Acknowledgements
This work was supported by the National Center for Responsible Gaming (A.S.K.) and Deutsche Forschungsgemeinschaft (DFG, Grant PE1627/5-1 to J.P.).

Number of Figures: 6
Number of Tables: 4

Abstract
Gambling disorder is a behavioral addiction associated with impairments in value-based decision-making and cognitive control. These functions are thought to be regulated by dopamine within fronto-striatal circuits, but the role of altered dopamine neurotransmission in the etiology of gambling disorder remains controversial. Preliminary evidence suggests that increasing frontal dopamine tone might improve cognitive functioning in gambling disorder. We therefore examined whether increasing frontal dopamine tone via a single dose of the catechol-O-methyltransferase (COMT) inhibitor tolcapone would reduce risky choice in human gamblers (n=14) in a randomized double-blind placebo-controlled crossover study. Data were analyzed using hierarchical Bayesian parameter estimation and a combined risky choice drift diffusion model. Model comparison revealed a non-linear mapping from value differences to trial-wise drift rates, confirming recent findings. An increase in risk-taking under tolcapone vs. placebo was about five times more likely, given the data, than a decrease (BF = 0.2). Examination of drug effects on diffusion model parameters revealed that an increase in the value-dependency of the drift rate under tolcapone was about thirteen times more likely than a decrease (BF = .073). In contrast, a reduction in the maximum drift rate under tolcapone was about seven times more likely than an increase (BF = 7.51). Results add
to previous work on COMT inhibitors in behavioral addictions and to mounting evidence for the applicability of diffusion models in value-based decision-making. Future work should focus on individual genetic, clinical and cognitive factors that might account for heterogeneity in the effects of COMT inhibition.

**Significance statement**
Gambling disorder is associated with impairments in value-based decision-making and cognitive control, functions regulated by the neurotransmitter dopamine. Here we examined whether increasing frontal dopamine tone via the catechol-O-methyltransferase (COMT) inhibitor tolcapone would reduce risky choice in a group of gamblers. Computational modeling did not reveal consistent reductions in risky decision-making under tolcapone in gamblers. If anything, tolcapone increased risky choice. Future work should focus on individual genetic, clinical and cognitive factors that might account for heterogeneity in the effects of COMT inhibition.

**Introduction**
Gambling disorder is a prototypical behavioral addiction that shares behavioral and neural features with substance use disorders (Fauth-Bühler et al., 2017). Consequently, gambling disorder is now classified with substance-related and addictive disorders in the DSM-V (American Psychiatric Association, 2013). Because dysregulation in the dopamine system is implicated in substance use disorders (Robinson and Berridge, 1993; Volkow et al., 2017), similar dysregulation might exist in gambling disorder. Past studies have indeed identified changes in the dopamine system (Boileau et al., 2014, 2013; Clark et al., 2012; Joutsa et al., 2012; van Holst et al., 2018), but there is considerable heterogeneity in the direction of these group differences (Kayser, 2019), and the robustness of some of the reported effects has recently been questioned (Potenza, 2018).

This heterogeneity may partly explain the mixed results of past open-label and placebo-controlled trials of drugs targeting the dopamine system in gambling disorder. While the dopamine D2 antagonist olanzapine was not superior to placebo (Fong et al., 2008; McElroy et al., 2008), both the dopamine D1 receptor antagonist ecopipam (Grant et al., 2014) and the catechol-O-methyltransferase (COMT) inhibitor tolcapone (Grant et al., 2013) showed promising results. These different study outcomes could be related to different loci of dopaminergic effects. While olanzapine’s actions are thought to primarily impact striatal
function, ecopipam and tolcapone may act more cortically. Tolcapone in particular takes advantage of the fact that significant cortical dopamine inactivation is accomplished via degradation by COMT. Using tolcapone to inhibit COMT could therefore lead to a relatively specific increase in frontal dopamine availability (Kärenmäki et al., 2010), thereby augmenting top-down control.

Consistent with this idea, problem gambling is more frequent in gamblers who carry the more active Val/Val polymorphism of the COMT val158met allele (rs4680) (Grant et al., 2015), presumably leading to lower frontal dopamine tone. Tolcapone also reduced compulsivity in gamblers in proportion to its effect on fronto-parietal activity (Grant et al., 2013) and reduced temporal discounting in gamblers in proportion to its effect on fronto-striatal connectivity (Kayser et al., 2017). Further effects of tolcapone relate to improvements in decision-making and executive control (Farrell et al., 2012; Kayser et al., 2015, 2012; Mitchell et al., 2018).

These domains are generally associated with impairments in gamblers, who show increased temporal discounting (Wiehler and Peters, 2015) and risk-taking (Ligneul et al., 2012; Miedl et al., 2012). In keeping with a dopaminergic influence on these functions, temporal discounting (Pine et al., 2010) and risk-taking (Rigoli et al., 2016; Rutledge et al., 2015) in control subjects are increased following the administration of the dopamine precursor L-DOPA, which is thought to boost dopamine availability more in the striatum than in the cortex (Lloyd and Hornykiewicz, 1972). Overall, however, the human literature is somewhat inconsistent about the direction of these effects (D’Amour-Horvat and Leyton, 2014). We have recently shown that a putative increase in striatal dopamine leads to a reduction in temporal discounting (Wagner et al., 2020), in keeping with rodent work demonstrating that moderate increases in striatal dopamine tend to improve impulse control. Another study only partly replicated the findings of Pine et al. (2010, such that the effects of L-DOPA depended on individual differences in self-control (Petzold et al., 2019). On the other hand, increasing frontal dopamine levels via COMT inhibition might more directly improve decision-making and impulse control, with potential effects of COMT genotype status (Farrell et al., 2012).

Given this hypothesis, we examined a subset of gamblers from a previous randomized, double-blind, placebo-controlled crossover study (Kayser et al., 2017) to assess whether increasing frontal dopamine levels via tolcapone would reduce risk-taking behavior in gamblers. Based on recent work in reinforcement learning (Fontanesi et al., 2019; Miletić et al., 2020; Pedersen et al., 2017; Shahar et al., 2019) temporal discounting (Peters and...
D’Esposito, 2020; Wagner et al., 2020) and risky choice (Peters and D’Esposito, 2020), we assessed decision making using a modeling framework based on the drift diffusion model (Ratcliff et al., 2016) in the context of a hierarchical Bayesian estimation scheme. This modeling approach has the benefit of accounting for the full response time (RT) distributions associated with decisions, thereby providing more detailed information regarding choice dynamics (Miletić et al., 2020; Pedersen et al., 2017) and more stable parameter estimates (Shahar et al., 2019). Furthermore, the drift diffusion model can provide novel insights into pharmacological effects on the dopamine system (Wagner et al., 2020). Based on these results, we examined whether a pharmacological modulation of frontal dopamine levels would likewise modulate choice dynamics in frequent gamblers during risky decision-making.
Methods

Participants

Participants were recruited via online advertisements. Subjects with South Oaks Gambling Screen (SOGS) scores > 5 (Lesieur and Blume, 1987) were invited to participate in screening procedures. This cut-off has been used clinically to minimize false negatives as opposed to false positives in the diagnosis of gambling disorder (Goodie et al., 2013). To further characterize the extent of their gambling, eligible participants then underwent the Structured Clinical Interview for Pathological Gambling (Grant et al., 2004), a validated instrument based on DSM-IV criteria.

Subjects were required to be between 18 and 50 years old, in good health, able to read and speak English, and able to provide informed consent. Subjects were excluded if, after completion of the Mini International Neuropsychiatric Interview (Sheehan et al., 1998), they met screening criteria for an axis I psychiatric disorder other than gambling disorder, such as major depression, or had a significant medical or psychiatric illness requiring treatment (see also below). Women of reproductive age were required to be using an effective form of contraception, and to be neither pregnant nor lactating during study participation. A positive urine drug toxicology screen before any visit was also grounds for exclusion, as was an alcohol level greater than zero as measured by breathalyzer before any visit. Similarly, subjects were excluded for reported use of psychoactive substances (including both prescription medications and drugs of abuse) within the prior two weeks, use of illicit drugs of abuse more than ten times in the previous year, or current dependence on marijuana. Subjects could otherwise use marijuana no more than three times per week and were required to refrain from marijuana use for at least 48 hours prior to testing sessions. Subjects who were taking medications with dopaminergic, serotonergic, or noradrenergic actions (although animal work suggests that tolcapone induces increases in dopaminergic but not noradrenergic concentrations (Tunbridge et al., 2004)) or who had a known allergy to either tolcapone or the inert constituents in tolcapone capsules, were also excluded. Because tolcapone carries the potential for hepatotoxicity, liver function tests as assessed by phlebotomy were required to be no more than three times the upper limit of normal.

Of the fourteen eligible subjects whose data were evaluated here, nine met the criteria for pathological gambling. Six also met criteria for current alcohol dependence. Because of the strong overlap between gambling disorder and alcohol use disorder, we did not exclude these
subjects, but they were required to have a negative breathalyzer test to consent and to participate in all study sessions. All fourteen participants had a 0.00 reading on the breathalyzer at the time of consent and at all subsequent study visits. We also did not exclude subjects who used nicotine, and the two regular smokers (out of four total nicotine-using subjects) were both easily able to refrain for the duration of specific study sessions. Table 1 provides an overview of the clinical and demographic data of all participants. The study procedure was approved by the local institutional review board and participants provided written informed consent prior to participation.

Table 1. Demographic and clinical characteristics of the gamblers. *South Oaks Gambling Screen (Lesieur and Blume, 1987), *Gambling-Related Cognitions Scale (Raylu and Oei, 2004), *Beck Depression Inventory (Beck et al., 1996), *Alcohol Use Disorders Identification Test (Saunders et al., 1993), *Barratt Impulsivity Scale (Patton et al., 1995). YoE – Years of Education. COMT – Catechol-O-Methyltransferase.

| N / Mean (SD) | Range |
|---------------|-------|
| N female/male | 6/8   |
| N Smokers/Nonsmokers | 4/10 |
| COMT genotype (Val/Val, Val/Met, Met/Met) | 7/4/3 |
| Age          | 32.57 (9.03) | 20-47 |
| YoE          | 14.93 (1.86) | 12-18 |
| SOGS*        | 10.79 (3.07) | 6-18 |
| GRCS Total b | 97.79 (14.08) | 76-116 |
| BDI c        | 11.79 (7.89) | 0-27 |
| AUDIT d      | 11.93 (6.40) | 2-20 |
| BIS*         | 70.5 (9.62)  | 50-88 |

Control group

Following the suggestion by two anonymous Reviewers, we compared the data from the gamblers under placebo to data from a set of control participants (n=19) from a previous study (Peters and D’Esposito, 2020). It should be noted, however, that these groups were not matched to the gamblers on age, such that control participants were older on average.

Drug administration

Subjects were randomized in double-blind, placebo-controlled, crossover fashion to either placebo or a single 200mg dose of tolcapone on their first visit and the alternative treatment
on their second visit. This dose was based upon previously published findings that a single 200mg dose has measurable behavioral effects (Kayser et al., 2015, 2012; Sáez et al., 2015).

The present behavioral testing session took place after completion of a functional magnetic resonance imaging (fMRI) study (Kayser et al., 2017). Subjects began the current task approximately 3 hours after tolcapone and placebo ingestion. Tolcapone is expected to have pharmaco-dynamically relevant serum concentrations for at least 6 hours (Dingemanse et al., 1995; Nyholm, 2006) and levels remain markedly above baseline well past 3 hours (Jorga et al., 1999, 2000). No subjects reported potential side effects under either the placebo or tolcapone conditions during their participation, and subjects could not reliably differentiate tolcapone from placebo. At the end of each study session, they were asked to guess whether they received tolcapone or placebo. Across the total of 28 choices (14 subjects x 2 sessions), participants correctly identified tolcapone and placebo 50% of the time (14 choices out of 28).

Risk-taking task

On each testing day, participants completed 112 trials of a risky-choice task involving a series of choices between a smaller, certain reward ($10 with 100% probability) and larger, but riskier, options. A first set of risky options consisted of all combinations of sixteen reward amounts (10.1, 10.2, 10.5, 11, 12, 15, 18, 20, 25, 30, 40, 50, 70, 100, 130, 150 dollars) and seven probabilities (10%, 17%, 28%, 54%, 84%, 96%, 99%). We used a second set of probabilities (11%, 18%, 27%, 55%, 83%, 97%, 98%) in combination with the same series of reward amounts to create a second set of 112 trials. The assignment of the two sets of trials to the two drug conditions was randomized across participants. The experiment was implemented in Presentation© (Neurobehavioral Systems). Trials were presented in randomized order and with a randomized assignment of safe/risky options to the left/right side of the screen. Both options remained on the screen until a response was made. An fMRI version of this task has previously been shown to have good test-retest reliability (Menz et al., 2012; Peters and Buchel, 2009) and has been successfully applied to characterize neural correlates of risky decision-making and subjective value in healthy young participants (Menz et al., 2012; Peters and Buchel, 2009).

Computational modeling

Risky choice model
We applied a simple single-parameter discounting model to describe how value changes as a function of probability, such that discounting is hyperbolic over the odds against winning the gamble (Green and Myerson, 2004; Menz et al., 2012; Peters and Buchel, 2009):

\[ SV(\text{risky}_t) = \frac{A_t}{1 + (\exp(h + s \cdot I_t) \cdot \theta_t)}, \text{with } \theta_t = \frac{1 - p_t}{p_t} \]  

Here, \( A \) is the numerical reward amount of the risky option, \( \theta \) is the odds against winning and \( I \) is an indicator variable that takes on a value of 1 for tolcapone data and 0 for placebo data.

The model has two free parameters: \( h \) is the hyperbolic discounting rate from the placebo condition (modeled in log-space) and \( s \) is a weighting parameter that models the degree of reduction in discounting under tolcapone vs. placebo. Thus, the smaller the value of \( h \), the smaller the weighting of the odds against winning, and the greater the subjective value of the risky option.

**Choice rules**

We used two different approaches to model participants’ behavior. First, we used softmax action selection to model binary (categorical) decisions. Second, we used the drift diffusion model to jointly account for choices and response times (RTs).

**Softmax action selection**

Softmax action selection models the choice probabilities as a sigmoid function of value differences (Sutton and Barto, 1998):

\[ P(\text{risky}_t) = \frac{e^{\beta \cdot SV(\text{risky}_t)}}{e^{\beta \cdot SV(\text{risky}_t)} + e^{\beta \cdot SV(\text{safe}_t)}} \]  

Here, \( SV \) is the subjective value of the risky reward according to Eq. 1 and \( \beta \) is an inverse temperature parameter, modeling choice stochasticity (for \( \beta = 0 \), choices are random and as \( \beta \) increases, choices become more dependent on the option values).

**Drift diffusion choice rule**

To better characterize the dynamics of the decision process, we replaced softmax action selection (Eq. 2) with the drift diffusion model (DDM), based on recent work in reinforcement learning (Fontanesi et al., 2019; Pedersen et al., 2017; Shahar et al., 2019). The DDM accounts not only for binary choices but for the full reaction time distributions associated with those decisions. We used the Wiener Module (Wabersich and Vandekerckhove, 2014) for the JAGS statistical modeling package (Plummer, 2003) that implements the likelihood function of a Wiener diffusion process. The DDM assumes that
decisions arise from a noisy evidence accumulation process that terminates as the accumulated evidence exceeds one of (usually) two decision bounds. Reinforcement learning applications of the DDM have used accuracy coding to define the response boundaries of the DDM (Fontanesi et al., 2019; Pedersen et al., 2017; Shahar et al., 2019), such that the upper boundary corresponds to selections of the objectively superior stimulus, and the lower boundary to choices of the inferior option. This structure is in line with the traditional application of the DDM in the context of perceptual decision-making tasks (Ratcliff and McKoon, 2008). However, in value-based decision-making, there is typically no objectively correct response. Therefore, previous applications of the DDM in this domain have instead recoded accuracy to correspond to the degree to which decisions are consistent with previously obtained preference judgements (Milosavljevic et al., 2010). This approach is not possible, however, when the goal is to use the DDM to model the preferences that in such a coding scheme would determine the boundary definitions. Therefore, here we applied stimulus coding, such that the upper boundary (1) corresponded to the selection of the risky option and the lower boundary (0) to the selection of the certain option.

We used percentile-based cut-offs for RTs, such that for each participant, the fastest and slowest 2.5% of trials were excluded. Excluding such outlier trials is common practice in the application of the DDM (Pedersen et al., 2017). The reason is that fast outlier trials force the modeled RT distribution to shift as far towards 0 as required to accommodate these observations. This can substantially reduce the goodness-of-fit of the model, because a single outlier RT that is not part of the typical ex-gaussian-shaped distribution can force the entire distribution to shift, thereby substantially reducing model fit and impacting group-level parameters.

RTs for choices of the certain 100% option were then multiplied by -1 prior to model estimation. The RT on a given trial is then distributed according to the Wiener First Passage Time (WFPT):

$$RT_i \sim WFPT(\alpha, \tau, z, v) \quad (3)$$

Here, $\alpha$ is the boundary separation (modeling response caution and influencing the speed-accuracy trade-off), $z$ is the starting point of the diffusion process (modeling a bias towards one of the decision boundaries), $\tau$ is the non-decision time (reflecting perceptual and/or response preparation processes unrelated to the evidence accumulation process) and $v$ is the drift rate (reflecting the rate of evidence accumulation). In the JAGS implementation of the Wiener model (Wabersich and Vandekerckhove, 2014), the starting point $z$ is coded in relative terms and takes on values between 0 and 1. That is, $z = .5$ reflects no bias, $z > .5$
reflects a bias towards the upper (risky option) boundary, and \( z < 0.5 \) reflects a bias towards the lower (certain option) boundary.

We then compared three variants of the DDM: First, we examined a null model (DDM0) without any value modulation. In this model, the four DDM parameters (\( \alpha, \tau, z, \) and \( v \)) were held constant across trials. Drug effects were modeled by including a term modeling a tolcapone-induced change relative to the placebo condition for each parameter. Second, we examined two previously proposed functions linking trial-by-trial changes in the drift rate \( v \) to value-differences. We examined a linear mapping (DDMlin) as previously proposed (Pedersen et al., 2017):

\[
v_t = v_{\text{coeff}} \cdot (SV(risky_t) - SV(safe_t)) \quad (4)
\]

Here, \( v_{\text{coeff}} \) maps trial-wise value differences onto the drift rate \( v \). \( SV \) is the subjective value of the rewards according to Eq. 1.

We also examined a recently proposed non-linear (DDMS) scheme (Fontanesi et al., 2019):

\[
v_t = S(v_{\text{coeff}} \cdot (SV(risky_t) - SV(safe_t))) \quad (5)
\]

\[
S(m) = \frac{2 \cdot v_{\max}}{1 + e^{-m}} - v_{\max} \quad (6)
\]

Here, \( S \) is a sigmoid function centered at 0 with \( m \) being the scaled value difference from Eq. 5, and asymptote \( \pm v_{\max} \). For DDMlin and DDMS, effects of choice difficulty on response times naturally arise. For more similar values, the trial-wise drift rate approaches 0.

Hierarchical Bayesian models

Model building proceeded as follows. As a first step, all models were fit at the level of individual participants. We validated that good fits could be obtained, such that posterior distributions were centered at sensible parameter values and the Gelman-Rubin \( \hat{R} \) statistic, an estimate of the degree of Markov chain convergence (see below), was in an acceptable range of \( 1 \leq \hat{R} \leq 1.01 \). In a second step, models were fit in a hierarchical manner with group-level distributions for all parameters. We used the same convergence criteria as for the single-subject models (\( 1 \leq \hat{R} \leq 1.01 \)). For group level hyper-parameters, we used weakly informative priors (i.e. uniform distributions defined over sensible ranges for means, gamma distributions for precision). Here, models were fit separately to the data from the placebo and tolcapone conditions, to examine whether drug administration altered the relative model ranking. Finally, after identifying the variant of the drift diffusion model that accounted for both the placebo and tolcapone data best, we fit this model across drug conditions. In this
final combined model, parameters from the placebo condition were modeled as the “baseline”, and all drug effects were modeled as Gaussians with group level priors with $\mu = 0, \sigma = 2$.

Data availability

Data cannot be shared publicly because participants did not consent to have their data posted in a public repository. Data are available from https://zenodo.org/record/3760335 for researchers who meet the criteria for access to confidential data.

Code accessibility

JAGS model code is available on the Open Science Framework (https://osf.io/wtg89/).

Model estimation and comparison

Models were fit using Markov Chain Monte Carlo (MCMC) as implemented in JAGS (Plummer, 2003) (Version 4.2) with the matjags interface (https://github.com/msteyvers/matjags) for Matlab (Mathworks) and the JAGS Wiener module (Wabersich and Vandekerckhove, 2014). For each model, we ran two chains with a burn-in period of 100k samples and thinning of 2. 10k additional samples were then retained for further analysis. Chain convergence was assessed via the $R$ statistic, where we considered $1 \leq R \leq 1.01$ as acceptable values for all group- and individual-level parameters. Relative model comparison was performed via the Deviance Information Criterion (DIC), where lower values indicate a better fit (Spiegelhalter et al., 2002).

Posterior predictive checks

We additionally performed posterior predictive checks to ensure that the best-fitting model captured key aspects of the data. Therefore, during model estimation, we simulated 10k full datasets from the hierarchical models based on the posterior distribution of parameters. For each participant and drug condition, model-predicted RT distributions for a random sample of 1k of these simulated data sets were then smoothed with non-parametric density estimation (ksdensity.m in Matlab) and overlaid on the observed RT distributions for each subject and drug condition.

Analysis of drug effects
We characterize drug effects in the following ways. First, we show group posterior distributions for all parameters, and 85% and 95% highest density intervals for the posterior distributions of the tolcapone-induced changes in parameters (shift parameters). Additionally, we report Bayes Factors for directional effects (Marsman and Wagenmakers, 2017; Pedersen et al., 2017) based on the posterior distributions of these shift parameters. This value was determined via non-parametric kernel density estimation in Matlab (ksdensity.m) and computed as $BF = i/(1 - i)$, where $i$ is the integral of the posterior distribution from 0 to $\infty$. Following common criteria, Bayes Factors $>3$ indicate support for a model, whereas Bayes Factors $>12$ indicate substantial support. Conversely, Bayes Factors $<.33$ are interpreted as evidence in favor of the alternative model. Lastly, we report standardized effect sizes for all drug-induced changes and group differences, which we calculated based on the means of the group-level posterior mean and precision parameters of the hierarchical model.

**Genetics**

DNA extraction and SNP analysis were performed on salivary samples (salimetrics.com) collected during the screening visit. DNA was extracted using Gentra Puregene reagents and protocols and quantified using the Pico Green method (Molecular Probes/Invitrogen). Genotyping of the cathechol-O-methyltransferase (COMT; rs4680) polymorphism via polymerase chain reaction was carried out using TaqMan® technology (Applied Biosystems).

Figure 1. a) Overall response time (RT) distributions for placebo (blue) and tolcapone (red). Here, positive RTs reflect choices of the risky option, and negative RTs reflect choices of the safe option. b) Proportion of choices of the risky option per participant and drug-condition. c) Median RT per participant and drug condition.

**Results**

**Model-free analyses**

Response time (RT) distributions across participants per drug condition are shown in Figure 1a. Arcsine-square-root transformed risky choice ratios (Figure 1b) did not differ significantly
between drug conditions ($t_{13} = -0.677$, $p = 0.51$, 95% CI: [-0.18, 0.095]). Likewise, median RTs did
not differ significantly between drug conditions ($t_{13} = -0.184$, $p = 0.857$, 95% CI: [-0.32, 0.27]),
arguing that tolcapone did not induce low-level motor effects.

Figure 2. Top row: Group-level posterior distributions for parameter means under placebo (solid
black line, a: softmax inverse temperature, b: log(h) [risk-taking]). The dashed blue lines plot the
group posterior distributions from the control group of a previous study ($n = 19$, Peters & D’Esposito,
2020). Center row: group level posterior distributions for tolcapone-induced changes for each
parameter. Bottom row: posterior distributions of group differences between gamblers under placebo
from the present study and the control group from Peters & D’Esposito (2020). The thin (thick)
horizontal lines in the center and bottom row indicate 95% (85%) highest density intervals.

Table 2. Left: summary of group differences in softmax model parameters. For each parameter, we
report the mean group difference (controls – gamblers_{placebo}), standardized effect sizes (Cohen’s $d$) (see
methods section) and Bayes Factors (BF) testing for directional effects (Marsman and Wagenmakers,
2017; Pedersen et al., 2017). Bayes Factors < 0.33 indicate evidence for a increase in gamblers_{placebo}
vs. controls, whereas Bayes Factors > 3 indicate evidence for a reduction (see methods section). Right:
summary of tolcapone effects on softmax model parameters. For each parameter we report the mean
change under tolcapone vs. placebo, standardized effect sizes (Cohen’s $d$) and Bayes Factors testing
for directional effects. Here, Bayes Factors > 3 indicate evidence for an increase under tolcapone,
whereas Bayes Factors < 0.33 indicate evidence for a decrease.

| Softmax model parameter | Group Difference | Tolcapone Effect |
|-------------------------|-----------------|-----------------|
|                         | $M_{diff}$ | $d$   | BF  | $M_{diff}$ | $d$   | BF  |
| Inverse temperature ($\beta$) | .065 | .698 | 9.36 | .005 | .048 | 1.28 |
| Log(h)                  | .479 | .263 | 3.59 | -.234 | .169 | .384 |
Softmax choice rule

In a first step we fit with a hyperbolic probability discounting model (Eq. 1) in combination with softmax action selection (Eq. 2). Posterior distributions under placebo as well as group and tolcapone effects are summarized in Figure 1 and Table 2. Compared to the control group from Peters & D’Esposito (2020), gamblers under placebo if anything showed greater risk taking (BF=3.59) and greater decision noise (smaller inverse temperature, BF=9.36). Tolcapone had no detectable effect on decision noise (BF=1.28) and, if anything, reduced probability discounting in gamblers (BF=.384).

Model comparison

We next focused on drift diffusion model choice rules, and compared three variants of the DDM: a null model without any value modulation (DDM₀), a model with a linear scaling of trial-wise drift rates (DDM_{lin}) and a model with non-linear (sigmoid) drift rate scaling (DDMₕ). To ensure that drug condition did not impact model ranking, we first fit the three models separately to the data from the placebo and tolcapone conditions. As can be seen from Table 3, model ranking was the same in the two drug conditions, such that models including value modulation of the drift rate outperformed the DDM₀, and the non-linear DDMₕ fit the data better than the DDM_{lin}.

Table 3. Model comparison of the drift diffusion models, separately for the two drug conditions. Under both placebo and tolcapone, the data were best accounted for by a model including a non-linear mapping from trial-wise value-differences to drift rates (DDMₕ).

| Model   | Placebo DIC | Placebo Rank | Tolcapone DIC | Tolcapone Rank |
|---------|-------------|--------------|---------------|----------------|
| DDM₀    | 42383       | 3            | 43177         | 3              |
| DDM_{lin} | 36136       | 2            | 38302         | 2              |
| DDMₕ    | 30354       | 1            | 32240         | 1              |
Initial model validation

We next fit the DDMs to the combined data from the two drug conditions, modeling the placebo condition as the baseline, and tolcapone-induced changes in each parameter as additive changes relative to that baseline using Gaussian priors centered at zero. As an initial validation analysis, we checked whether the choice model parameters estimated via a standard softmax choice rule (Equation 2) could be reproduced using the DDM. We therefore correlated single subject mean posteriors for \( \log(h) \) (risk taking under placebo) and \( \log(h)_{\text{tolcapone}} \) (the change in risk taking under tolcapone) from the hierarchical DDMs and the hierarchical model with softmax action selection (see Figure 3). Both parameters were highly correlated between estimation schemes (\( \log(h): r = .98, p < .0001 \), \( \log(h)_{\text{tolcapone}}: r = .93, p < .0001 \)), indicating that parameters estimated via standard methods could be reproduced using the DDM (Peters and D’Esposito, 2020).

Posterior predictive checks

Then we examined the extent to which the DDMs could reproduce the reaction time distributions observed in individual participants. To this end, we simulated 10k full datasets from the models’ posterior distribution. The histograms in Figure 4 show the observed reaction time distribution for each participant and drug condition, with a smoothed density estimate of the model-generated reaction time distribution (based on 1000 random samples from the simulations) overlaid. Generally, the model accounted reasonably well for the observed reaction time distributions in most participants. The DDM also accounted for a similar proportion of binary decision under tolcapone and placebo (M[range]placebo: .899 (.798-.962), M[range]tolcapone: .879 (.717-.972), \( t_{13} = 1.21, p = .249 \)).
Figure 4. Posterior predictive plots of the drift diffusion temporal discounting model with non-linear value scaling of the drift rate (DDM$_S$) for all fourteen participants (blue: placebo, red: tolcapone). Histograms depict the observed RT distributions for each participant. The solid lines are smoothed histograms of the model predicted RT distributions from 1k individual subject data sets simulated from the posterior of the best fitting hierarchical model. RTs for smaller-sooner choices are plotted as negative, whereas RTs for larger-later choices are plotted as positive. The x-axes are adjusted to cover the range of observed RTs for each participant.
Figure 5. Top row: Group-level posterior distributions for parameter means in the gamblers under placebo (n=14, solid black line) and the Peters & D’Esposito (2020) controls (n=19, solid blue line). a: boundary separation, b: non-decision time, c: bias, d: vmax, e: vcoeff, f: log(h) [risk-taking]. The dashed red line in c) denotes 0.5, i.e. a neutral bias. The dashed red line in e) denotes zero, i.e., no value modulation of the drift rate. Center row: group level posterior distributions for tolcapone-induced changes for each parameter. Bottom row: posterior distributions of group differences between gamblers under placebo from the present study and the control group from Peters & D’Esposito (2020). The thin (thick) horizontal lines in the center and bottom row indicate 95% (85%) highest density intervals.

Table 4. Left: summary of group differences in DDM model parameters. For each parameter, we report the mean group difference (controls – gamblersplacebo), standardized effect sizes (Cohen’s $d$) (see methods section) and Bayes Factors (BF) testing for directional effects (Marsman and Wagenmakers, 2017; Pedersen et al., 2017). Bayes Factors <.33 indicate evidence for an increase in gamblersplacebo vs. controls, whereas Bayes Factors >3 indicate evidence for a reduction (see methods section). Right: summary of tolcapone effects on DDM model parameters. For each parameter we report the mean change under tolcapone vs. placebo, standardized effect sizes (Cohen’s $d$) and Bayes Factors testing for directional effects. Here, Bayes Factors >3 indicate evidence for an increase under tolcapone, whereas Bayes Factors <.33 indicate evidence for a decrease.

| DDM model parameter | Group Difference | | | | Tolcapone Effect | |
|---------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                     | $M_{diff}$ | $d$ | BF | $M_{diff}$ | $d$ | BF |
| Boundary separation ($\alpha$) | .966 | 1.15 | 328.0 | .063 | .089 | 1.81 |
| Non decision time ($\tau$) | .328 | .784 | 14.87 | -.003 | -.031 | .815 |
| Starting point / bias ($z$) | -.011 | -.211 | .403 | .004 | .088 | 1.47 |
| Drift rate $v$ (max) | -.236 | -.741 | .065 | -.166 | -1.84 | .073 |
| Drift rate $v$ (coeff) | -.047 | -.865 | .181 | .069 | .910 | 7.51 |
| Log(h) | .575 | .344 | 4.40 | -.286 | -.281 | .20 |

Effects of tolcapone on risk-taking and diffusion model parameters

We next examined the posterior distributions of parameters of the final DDMs model in more detail. Figure 5 (top row) shows the group level posterior distributions for parameters at baseline (placebo) as well as parameters for the Peters & D’Esposito (2020) control group.
Figure 5 (center row) shows posterior distributions for tolcapone effects, and the bottom row shows posterior group differences (gamblersplacebo vs. controls). Mean group differences, tolcapone effects and Bayes Factors testing for directional effects are listed in Table 4. Under placebo, both boundary separation (response caution, Fig. 5a, Table 4) and non-decision time (Fig. 5b, Table 4) in the gamblers under placebo were substantially lower than the corresponding values in the control group. Both groups also exhibited a bias towards the safe option, reflected in a posterior distribution of the starting point that was shifted slightly towards zero (Fig. 5c). The maximum drift rate $v_{max}$ at placebo was higher in gamblers vs. controls (Fig. 5d, Table 4) and there was a robust positive effect of value-differences on the trial-wise drift rates, as reflected in a positive drift rate coefficient parameter under placebo ($v_{coeff}$, Fig. 5e). Interestingly, $\log(h)$ (i.e. risk-taking) in the gamblers under placebo (Fig. 5f) was higher compared to our previous control group, such that increased risk-taking in gamblers was about 4.4 times more likely than a reduction. Notably, a $\log(h)$ value of 0 would indicate risk neutrality such that the subjective value of a risky option corresponds to its expected value. Both groups were therefore risk averse, but gamblers less so than controls.

All drug effects are summarized in the right columns of Table 4 (mean parameter changes between tolcapone and placebo, standardized effect sizes (Cohen’s $d$), Bayes Factors for directional effects; see methods section). The posterior distributions for the tolcapone-induced change for boundary separation (Fig. 5a), non-decision time (Fig. 5b) and starting point (Fig. 5c) were all centered at zero with effect sizes of $|d|<.1$. In contrast, under tolcapone, there was evidence for a decrease in the maximum drift rate ($v_{max}$) ($d = -1.84$, BF = .073), an increase in the value-dependent drift-rate modulation ($d = .901$, BF = 7.51) and for a relative increase in risky decision-making as indexed by the hyperbolic discount rate $h$ ($d = -.281$, BF = .20). Tolcapone thus, if anything, shifted risk preferences in the gamblers towards risk neutrality.

Compensation between drift rate components

Because previous reports suggested a negative association between $v_{max}$ and $v_{coeff}$ (Fontanesi et al., 2019), we examined whether there might also be some compensation between these parameters in our data. We therefore ran additional models where we fixed either drift rate component under tolcapone to that parameter’s value under placebo (that is, keeping either parameter constant while allowing the other to vary according to the drug condition). When $v_{max}$ was fixed to the placebo value, there was no longer any evidence for a drug-induced change in $v_{coeff}$ (BF=1.36, as compared to BF=7.51 in the full model). In contrast, when $v_{coeff}$
was fixed to the placebo value, the reduction in $v_{\text{max}}$ was still observed, though somewhat attenuated (BF=.17 as compared to BF=.073 in the full model). Full results from these models are available at OSF (https://osf.io/wtg89/)

Figure 6. Posterior group means (solid black lines) and individual subject posterior distributions (grey: Val/Val and Val/Met, red: Met/Met) for the tolcapone-induced changes in maximum drift rate (a), in value-dependent drift rate modulation (b) and in the probability discount rate (c). The mean change in $v_{\text{max}}$ was < 0 in 13/14 subjects. In $v_{\text{coeff}}$ it was > 0 in 12/14 subjects and in $\log(h)$ it was < 0 in 9/14 subjects.

Consistency of tolcapone effects across participants

We finally examined the consistency of the latter three group effects across participants by overlaying individual posterior distributions for the tolcapone-effects over the average group effects for parameters showing drug-effects at the group level (Figure 6a: $v_{\text{max}}$, Figure 6b: $v_{\text{coeff}}$, Figure 6c: $\log(h)$). Under tolcapone, 13/14 participants showed a mean reduction in the maximum drift rate $v_{\text{max}}$, 12/14 showed an increase in the drift rate scaling $v_{\text{coeff}}$, and 9/14 showed a decrease in $\log(h)$ (increase in risk-taking). For transparency, we have highlighted the three Met/Met genotype participants in these plots (red lines), though the analysis of genotype effects is underpowered.
Gambling disorder is associated with impairments in value-based decision-making, including increased temporal discounting and reduced risk aversion (Wiehler and Peters, 2015). Here we tested whether risky decision-making in gamblers could be attenuated by the COMT inhibitor tolcapone, which predominantly increases dopamine levels in the frontal cortex. Choice data were modeled in a hierarchical Bayesian scheme with the drift diffusion model as the choice rule to account for both choices and reaction time distributions. In contrast to our initial hypothesis, if anything tolcapone increased risky decision-making (small effect size) by shifting preferences in gamblers more towards risk neutrality. Examination of the drift diffusion model parameters showed a reduction in the maximum drift rate under tolcapone (large effect size) and an increase in the value-dependency of the drift rate (large effect size). Together these results suggest that tolcapone might tie decision-making more tightly to subjective value differences, but that the subjective value of risky options is possibly increased.

We used a modeling scheme based on the drift diffusion model, which has recently gained some popularity in reinforcement learning and value-based decision-making (Fontanesi et al., 2019; Pedersen et al., 2017; Peters and D’Esposito, 2020; Shahar et al., 2019; Wagner et al., 2020). As was reported in previous work (Peters and D’Esposito, 2020) choice model parameters estimated via a standard softmax function could be reliably reproduced using the drift diffusion model as the choice rule. Posterior predictive checks revealed that the best-fitting drift diffusion model reproduced individual subject reaction time distributions reasonably well in both drug conditions. In keeping with previous work on DDM choice rules (Fontanesi et al., 2019; Peters and D’Esposito, 2020), we carried out a model comparison and evaluated both a linear and non-linear mapping from value-differences to trial-wise drift rates. The non-linear DDM fit the data better in both drug conditions, confirming previous results of non-linear drift rate scaling.

The control group was not matched to the gamblers on demographic variables, such that some caution is warranted when interpreting the group differences. However, it is interesting to see that gamblers under placebo exhibited substantially more premature responding than controls (lower boundary separation) as well as faster non-decision times, which could be expected given that increased motor impulsivity is often observed in gambling disorder (Chowdhury et al., 2017). Furthermore, an increase in risky decision-making in gamblers vs. controls was about 4.4 times more likely, given the data, than a reduction, which is in line with previous findings of increased risk-taking in gamblers (Ligneul et al., 2012;
Miedl et al., 2012). Notably, both groups were overall risk averse (log(h) was substantially > 0), such that gamblers preferences were shifted more towards risk neutrality than controls.

Our results suggest small effects (|d|<.1) of tolcapone on three parameters of the drift diffusion model: boundary separation, non-decision time and starting point (bias). This finding suggests that overall response caution (as reflected in the boundary separation parameter) and processes related to motor preparation and/or stimulus processing (as reflected in the non-decision time) were largely unaffected by tolcapone. In contrast, there was some evidence that tolcapone modulated drift rate components, and if anything, reduced probability discounting in gamblers, compared to placebo. The latter effect was similarly observed for the standard softmax choice rule and for the DDM. What mechanism might drive the observed effects of tolcapone on risky decision-making and value evidence accumulation? Our approach was motivated by the idea that tolcapone might attenuate risky choice via an augmentation of prefrontal cortex (top-down control) functions. The lateral prefrontal cortex is implicated in cognitive control (Miller and Cohen, 2001; Szczepanski and Knight, 2014), and disruption of prefrontal cortex function can increase risk-taking and impulsivity (Figner et al., 2010; Knoch et al., 2006; Peters and D’Esposito, 2020, 2016; Sellitto et al., 2010). Likewise, tolcapone has been shown to act through an enhancement of prefrontal cortex activation and/or fronto-striatal interactions (Grant et al., 2013; Kayser et al., 2017, 2012).

However, although the drug-effect on risky choice was small, it was in the opposite direction, increasing risky choice rather than attenuating it. Furthermore, the directionality and effect size of the drug-effect on log(h) showed some heterogeneity across participants (Figure 6c). In the absence of task-related imaging data, drawing definite conclusions regarding the mechanism underlying these differential effects of tolcapone on risky choice remains speculative, and individual genetic differences likely contribute to these variable results.

Similarly, it remains unclear through what exact mechanism an increase of frontal dopamine levels might affect the changes in value-dependency of the drift-rate observed in the present study. Ventromedial prefrontal cortex is involved in coding for reward valuation during learning and decision-making (Bartra et al., 2013; Clithero and Rangel, 2014). It could thus be speculated that tolcapone might enhance such value representations, thereby increasing the value-dependency of trial-wise drift rates. However, at the same time maximum drift rates were reduced under tolcapone, an effect that was consistent across participants (see Figure 6). Additional analyses revealed that this might in part reflect at a trade-off between \( v_{\text{max}} \) and \( v_{\text{coeff}} \) parameters in the model, such that reduced \( v_{\text{max}} \) can be
compensated for by increases in $v_{c_{off}}$ under some conditions. Such interactions require further study in the use of diffusion model choice rules in larger samples.

Finally, dopamine has different functions in different prefrontal cortex subregions (Robbins and Arnsten, 2009), such that different dopamine-dependent cognitive functions might exhibit different dose-response functions (Floresco, 2013) and thus be differentially modulated by tolcapone. A thorough assessment of these complexities, including process-dependent baseline effects and potential subregion-specific effects of tolcapone will need to be more fully addressed in future studies (Kayser, 2019).

While we genotyped participants for the COMT Val158Met polymorphism, drawing any conclusions regarding genotype effects in a small sample study such as the present one is obviously highly problematic. On the other hand, not reporting genotype data that is available would also seem inappropriate given the previously suggested COMT genotype-dependency of tolcapone effects on risk-taking (Farrell et al., 2012). In their between-subjects study, Farrell and colleagues (Farrell et al., 2012) reported increased risk-aversion in Val/Val participants under tolcapone, compared to a group of Met/Met carriers. In contrast to that study, in our data set the two participants showing the largest reduction in risky choice under tolcapone were Met/Met carriers. This result is in line with the frequent observation that dopamine effects on cognitive functions mediated by the prefrontal cortex depend on baseline dopamine availability in an inverted-U-shaped fashion (Cools and D’Esposito, 2011). Yet, in this model, Met/Met carriers exhibit a higher frontal dopamine level at baseline due to the COMT enzyme being less active. Further COMT suppression (e.g. via tolcapone) is then thought to move Met/Met subjects into an “overdosed” state, impairing performance relative to placebo (Cools and D’Esposito, 2011; Farrell et al., 2012; Tunbridge et al., 2006). This is not compatible with the substantial reduction in probability discounting observed for 2/3 Met/Met carriers. However, as mentioned above, different cognitive functions might show different functional forms of dopamine baseline-dependency (Floresco, 2013), which would require much larger subject numbers to fully evaluate.

There are several additional limitations of the present study that need to be acknowledged. First, given the small sample size, our findings require replication in larger samples and disorders other than gambling disorder. Second, although gender was relatively balanced in the present study, which is often not the case in gambling disorder, we were underpowered to examine sex differences. Third, we did not test a control group specifically matched to the gamblers and rather focused on potential drug-effects in this clinical sample. The aim of the project was to examine the degree to which behavioral markers of gambling
disorder such as risk-taking and temporal discounting (Kayser et al., 2017) could be improved
by COMT inhibition, but future studies could benefit from a more detailed exploration of the
effects of COMT inhibition on risk-taking in healthy controls, as done in a previous study for
inter-temporal choice (Kayser et al., 2012). However, to provide some reference for risk
preferences in our particular sample of gamblers, we have compared their parameters under
placebo to a group of and controls from a previous study in medial orbitofrontal cortex lesion
patients (Peters and D’Esposito, 2020, 2016). Finally, we focused on a simple single-
parameter risky choice model (hyperbolic probability discounting) (Green and Myerson,
2004), because two-parameter models (Lattimore et al., 1992; Ligneul et al., 2012) failed to
converge in our data. This is likely due to the somewhat limited range of probabilities and
amounts examined in our task. However, future studies would benefit from a more detailed
examination of e.g. elevation vs. curvature of the probability weighting function, as dopamine
has been suggested to differentially affect these processes (Burke et al., 2018; Ojala et al.,
2018).

Taken together, our data extend previous investigations of modeling schemes that
build on the drift diffusion model (Fontanesi et al., 2019; Pedersen et al., 2017; Peters and
D’Esposito, 2020; Wagner et al., 2020), by successfully applying this approach for the first
time in clinical sample. While the data are preliminary given the small sample size, they
suggest that tolcapone might impact aspects of value evidence accumulation during risky
choice. However, our data do not support the idea that tolcapone attenuates risk-taking in
gambling disorder. These results extend and complement previous examinations of the
potential of COMT inhibition in gambling disorder (Grant et al., 2013; Kayser et al., 2017) by
providing a comprehensive model-based analysis of risky decision-making.

References

American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition. ed. American Psychiatric Association.
Bartra O, McGuire JT, Kable JW (2013) The valuation system: a coordinate-based meta-
analysis of BOLD fMRI experiments examining neural correlates of subjective value.
NeuroImage 76:412–427.
Beck AT, Steer RA, Brown, G.K. (1996) Manual for the Beck Depression Inventory-II. San
Antonio, TX: Psychological Corporation.
Boileau I, Payer D, Chugani B, Lobo D, Behzadi A, Rusjan PM, Houle S, Wilson AA, Warsh
J, Kish SJ, Zack M (2013) The D2/3 dopamine receptor in pathological gambling: a positron
emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and
[11C]raclopride. Addiction 108:953–63.
Boileau I, Payer D, Chugani B, Lobo DSS, Houle S, Wilson AA, Warsh J, Kish SJ, Zack M
(2014) In vivo evidence for greater amphetamine-induced dopamine release in pathological
gambling: a positron emission tomography study with [(11)C]-(+)-PHNO. Mol Psychiatry
23
Burke CJ, Soutschek A, Weber S, Raja Beharelle A, Fehr E, Haker H, Tobler PN (2018) Dopamine Receptor-Specific Contributions to the Computation of Value. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 43:1415–1424.

Chowdhury NS, Livesey EJ, Blaszczynski A, Harris JA (2017) Pathological Gambling and Motor Impulsivity: A Systematic Review with Meta-Analysis. J Gambl Stud 33:1213–1239.

Clark L, Stokes PR, Wu K, Michaleczuk R, Benecke A, Watson BJ, Egerton A, Piccini P, Nutt DJ, Bowden-Jones H, Lingford-Hughes AR (2012) Striatal dopamine D2/D3 receptor binding in pathological gambling is correlated with mood-related impulsivity. NeuImage 63:40–46.

Clithero JA, Rangel A (2014) Informatic parcellation of the network involved in the computation of subjective value. Soc Cogn Affect Neurosci 9:1289–1302.

Cools R, D'Esposito M (2011) Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 69:113-25.

D'Amour-Horvat V, Leyton M (2014) Impulsive actions and choices in laboratory animals and humans: effects of high vs. low dopamine states produced by systemic treatments given to neurologically intact subjects. Front Behav Neurosci 8:432.

Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, van Brummelen P (1995) Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 57:508–517.

Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ (2012) COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry 71:538–544.

Fauth-Bühler M, Mann K, Potenza MN (2017) Pathological gambling: a review of the neurobiological evidence relevant for its classification as an addictive disorder. Addict Biol 22:885–897.

Figner B, Knoch D, Johnson EJ, Krosch AR, Lisanby SH, Fehr E, Weber EU (2010) Lateral prefrontal cortex and self-control in intertemporal choice. Nat Neurosci 13:538–539.

Floresco SB (2013) Prefrontal dopamine and behavioral flexibility: shifting from an “inverted-U” toward a family of functions. Front Neurosci 7:62.

Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L (2008) A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers.

Grant JE, Leppink EW, Redden SA, Odlaug BL, Chamberlain SR (2015) COMT genotype, gambling activity, and cognition. J Psychiatr Res 68:371–376.

Grant JE, Odlaug BL, Black DW, Fong T, Davtian M, Chipkin R, Kim SW (2014) A single-blind study of “as-needed” ecopipam for gambling disorder. Ann Clin Psychiatry Off J Am Acad Clin Psychiatry 26:179–186.

Grant JE, Odlaug BL, Chamberlain SR, Hampshire A, Schreiber LRN, Kim SW (2013) A proof of concept study of tolcapon for pathological gambling: relationships with COMT genotype and brain activation. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 23:1587–1596.

Grant JE, Steinberg MA, Kim SW, Rounsaville BJ, Potenza MN (2004) Preliminary validation and reliability testing of a structured clinical interview for pathological gambling. Psychiatry Res 128:79–88.

Green L, Myerson J (2004) A discounting framework for choice with delayed and...
probabilistic rewards. Psychol Bull 130:769–92.

Jorga K, Fotteler B, Banken L, Snell P, Steimer JL (2000) Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. Br J Clin Pharmacol 49:39–48.

Jorga K, Fotteler B, Heizmann P, Gasser R (1999) Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br J Clin Pharmacol 48:513–520.

Joutsa J, Johansson J, Niemelä S, Ollikainen A, Hirvonen MM, Piepponen P, Arponen E, Alho H, Voon V, Rinne JO, Hietala J, Kaasinen V (2012) Mesolimbic dopamine release is linked to symptom severity in pathological gambling. NeuroImage 60:1992–1999.

Käenmäki M, Tammimäki A, Myöhänen T, Pakarinen K, Amberg C, Karayiorgou M, Gogos JA, Männistö PT (2010) Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem 114:1745–1755.

Kayser A (2019) Dopamine and Gambling Disorder: Prospects for Personalized Treatment. Curr Addict Rep 6:65–74.

Jorga K, Fotteler B, Banken L, Snell P, Steimer JL (2000) Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. Br J Clin Pharmacol 49:39–48.

Jorga K, Fotteler B, Heizmann P, Gasser R (1999) Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br J Clin Pharmacol 48:513–520.

Joutsa J, Johansson J, Niemelä S, Ollikainen A, Hirvonen MM, Piepponen P, Arponen E, Alho H, Voon V, Rinne JO, Hietala J, Kaasinen V (2012) Mesolimbic dopamine release is linked to symptom severity in pathological gambling. NeuroImage 60:1992–1999.

Käenmäki M, Tammimäki A, Myöhänen T, Pakarinen K, Amberg C, Karayiorgou M, Gogos JA, Männistö PT (2010) Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem 114:1745–1755.

Kayser A (2019) Dopamine and Gambling Disorder: Prospects for Personalized Treatment. Curr Addict Rep 6:65–74.

Knoch D, Gianotti LRR, Pascual-Leone A, Treyer V, Regard M, Hohmann M, Brugger P (2006) Disruption of Right Prefrontal Cortex by Low-Frequency Repetitive Transcranial Magnetic Stimulation Induces Risk-Taking Behavior. J Neurosci 26:6469–6472.

Lattimore PK, Baker JR, Witte AD (1992) The influence of probability on risky choice: a parametric examination. J Econ Behav Organ 27:397–400.

Lesieur HR, Blume SB (1987) The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 144:1184–1185.

Ligneul R, Sescousse G, Barbalat G, Domenech P, Dreher JC (2012) Shifted risk preferences in pathological gambling. Psychol Med 1–10.

Lloyd KG, Hornykiewicz O (1972) Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J Neurochem 19:1549–1559.

Marsman M, Wagenmakers E-J (2017) Three Insights from a Bayesian Interpretation of the One-Sided P Value. Educ Psychol Meas 77:529–539.

McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE (2008) Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry 69:433–440.

Menz MM, Buchel C, Peters J (2012) Sleep Deprivation Is Associated with Attenuated Parametric Valuation and Control Signals in the Midbrain during Value-Based Decision Making. J Neurosci 32:6937–6946.

Miedl SF, Peters J, Büchel C (2012) Altered neural reward representations in pathological gamblers revealed by delay and probability discounting. Arch Gen Psychiatry 69:177–186.

Miletic S, Boag RJ, Forstmann BU (2020) Mutual benefits: Combining reinforcement learning with sequential sampling models. Neuropsychologia 136:107261.

Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24:167–202.

Milosavljevic M, Malmaud J, Huth A, Koch C, Rangel A (2010) The drift diffusion model can account for the accuracy and reaction time of value-based choices under high and low time pressure. Judgement Decis Mak 5:437–449.

Mitchell JM, Weinstein D, Vega T, Kayser AS (2018) Dopamine, time perception, and future time perspective. Psychopharmacology (Berl) 235:2783–2793.
Nyholm D (2006) Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet 45:109–136.

Ojala KE, Janssen LK, Hashemi MM, Timmer MHM, Geurts DEM, Ter Huurne NP, Cools R, Sesouesse G (2018) Dopaminergic Drug Effects on Probability Weighting during Risky Decision Making. eNeuro 5.

Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51:768–74.

Pedersen ML, Frank MJ, Biele G (2017) The drift diffusion model as the choice rule in reinforcement learning. Psychon Bull Rev 24:1234–1251.

Peters J, Buchel C (2009) Overlapping and Distinct Neural Systems Code for Subjective Value during Intertemporal and Risky Decision Making. J Neurosci 29:15727–15734.

Peters J, D’Esposito M (2020) The drift diffusion model as the choice rule in inter-temporal and risky choice: A case study in medial orbitofrontal cortex lesion patients and controls. PLOS Comput Biol 16:e1007615.

Peters J, D’Esposito M (2016) Effects of Medial Orbitofrontal Cortex Lesions on Self-Control in Intertemporal Choice. Curr Biol CB 26:2625–2628.

Petzold J, Kienast A, Lee Y, Poosheh S, London ED, Goschke T, Smolka MN (2019) Baseline impulsivity may moderate L-DOPA effects on value-based decision-making. Sci Rep 9:5652.

Pine A, Shiner T, Seymour B, Dolan RJ (2010) Dopamine, Time, and Impulsivity in Humans. J Neurosci 30:8888–8896.

Plummer M (2003) JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling In: Proceedings of the 3rd International Workshop on Distributed Statistical Computing, Technische Universit at Wien.

Potenza MN (2018) Searching for Replicable Dopamine-Related Findings in Gambling Disorder. Biol Psychiatry 83:984–986.

Ratcliff R, McKoon G (2008) The diffusion decision model: theory and data for two-choice decision tasks. Neural Comput 20:873–922.

Ratcliff R, Smith PL, Brown SD, McKoon G (2016) Diffusion Decision Model: Current Issues and History. Trends Cogn Sci 20:260–281.

Raylu N, Oei TPS (2004) The Gambling Related Cognitions Scale (GRCS): development, confirmatory factor validation and psychometric properties. Addict Abingdon Engl 99:757–769.

Rigoli F, Rutledge RB, Chew B, Ousdal OT, Dayan P, Dolan RJ (2016) Dopamine Increases a Value-Independent Gambling Propensity. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 41:2658–2667.

Robbins TW, Arnsten AFT (2009) The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 32:267–287.

Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18:247–291.

Rutledge RB, Skandali N, Dayan P, Dolan RJ (2015) Dopaminergic Modulation of Decision Making and Subjective Well-Being. J Neurosci Off J Soc Neurosci 35:9811–9822.

Sáez I, Zhu L, Set E, Kayser A, Hsu M (2015) Dopamine modulates egalitarian behavior in humans. Curr Biol CB 25:912–919.

Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction 88:791–804.

Sellitto M, Ciaramelli E, di Pellegrino G (2010) Myopic Discounting of Future Rewards after Medial Orbitofrontal Damage in Humans. J Neurosci 30:16429–16436.

Shahar N, Hauser TU, Moutoussis M, Moran R, Keramati M, NSPN consortium, Dolan RJ (2019) Improving the reliability of model-based decision-making estimates in the two-stage decision task with reaction-times and drift-diffusion modeling. PLoS Comput Biol
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl 20:22-33;quiz 34-57.

Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A (2002) Bayesian measures of model complexity and fit. J R Stat Soc Ser B Stat Methodol 64:583–639.

Sutton RS, Barto AG (1998) Reinforcement Learning: An Introduction. Cambridge, Massachusetts: MIT Press.

Szczepanski SM, Knight RT (2014) Insights into human behavior from lesions to the prefrontal cortex. Neuron 83:1002–1018.

Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ (2004) Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci Off J Soc Neurosci 24:5331–5335.

Tunbridge EM, Harrison PJ, Weinberger DR (2006) Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60:141–51.

van Holst RJ, Sescousse G, Janssen LK, Janssen M, Berry AS, Jagust WJ, Cools R (2018) Increased Striatal Dopamine Synthesis Capacity in Gambling Addiction. Biol Psychiatry 83:1036–1043.

Volkow ND, Wise RA, Baler R (2017) The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci 18:nrn.2017.130.

Wabersich D, Vandekerckhove J (2014) Extending JAGS: a tutorial on adding custom distributions to JAGS (with a diffusion model example). Behav Res Methods 46:15–28.

Wagner B, Clos M, Sommer T, Peters J (2020) Dopaminergic modulation of human inter-temporal choice: a diffusion model analysis using the D2-receptor-antagonist haloperidol. bioRxiv 2020.02.13.942383.

Wiehler A, Peters J (2015) Reward-based decision making in pathological gambling: the roles of risk and delay. Neurosci Res 90:3–14.

Extended Data 1

JAGS model code of all hierarchical models (DDM0, DDMlin and DDMs) is available as extended data at https://osf.io/wtg89/. Model parameters and the input data structure expected by the model are explained in detail in the header of each code file.